See more : Premier Anti-Aging Co., Ltd. (4934.T) Income Statement Analysis – Financial Results
Complete financial analysis of Shenzhen Bioeasy Biotechnology Co., Ltd. (300942.SZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Shenzhen Bioeasy Biotechnology Co., Ltd., a leading company in the Biotechnology industry within the Healthcare sector.
- SystemSoft Corporation (7527.T) Income Statement Analysis – Financial Results
- Road King Infrastructure Limited (1098.HK) Income Statement Analysis – Financial Results
- Samchully Co.,Ltd (004690.KS) Income Statement Analysis – Financial Results
- Canada Global (T.R) Ltd (CNGL.TA) Income Statement Analysis – Financial Results
- Shiseido Company, Limited (SSDOF) Income Statement Analysis – Financial Results
Shenzhen Bioeasy Biotechnology Co., Ltd. (300942.SZ)
About Shenzhen Bioeasy Biotechnology Co., Ltd.
Shenzhen Bioeasy Biotechnology Co., Ltd. develops and sells rapid testing instruments and reagents in China. The company offers detection equipment for use in the fields of food, agricultural, dairy, meat, aquatic, honey, drug, and public safety, as well as clinical diagnosis. Shenzhen Bioeasy Biotechnology Co., Ltd. was founded in 2007 and is based in Shenzhen, China.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
---|---|---|---|---|---|---|---|---|
Revenue | 254.11M | 686.90M | 597.54M | 258.46M | 239.18M | 204.93M | 137.89M | 87.05M |
Cost of Revenue | 127.23M | 298.76M | 169.51M | 63.67M | 65.86M | 64.79M | 33.80M | 22.09M |
Gross Profit | 126.87M | 388.14M | 428.03M | 194.79M | 173.32M | 140.14M | 104.09M | 64.95M |
Gross Profit Ratio | 49.93% | 56.51% | 71.63% | 75.37% | 72.46% | 68.38% | 75.49% | 74.62% |
Research & Development | 53.40M | 111.42M | 72.43M | 40.46M | 33.69M | 24.42M | 23.96M | 16.90M |
General & Administrative | 23.76M | 30.15M | 19.20M | 19.72M | -31.64M | -24.93M | -17.84M | 14.56M |
Selling & Marketing | 28.95M | 58.90M | 48.08M | 32.24M | 34.37M | 26.31M | 23.36M | 15.86M |
SG&A | 52.72M | 89.06M | 67.28M | 51.96M | 2.73M | 1.38M | 5.53M | 30.42M |
Other Expenses | 196.31M | -3.22M | -237.55K | -1.16M | -2.13M | -2.20M | -941.24K | 10.53M |
Operating Expenses | 302.18M | 250.43M | 160.08M | 102.24M | 75.41M | 56.19M | 58.40M | 48.21M |
Cost & Expenses | 428.83M | 549.19M | 329.59M | 165.91M | 141.27M | 120.98M | 92.20M | 70.31M |
Interest Income | 7.56M | 3.56M | 2.14M | 384.70K | 2.53M | 842.65K | 938.18K | 184.70K |
Interest Expense | 10.80M | 4.08M | 2.38M | 369.73K | 56.89K | 76.86K | 9.99K | 77.88K |
Depreciation & Amortization | 33.48M | 35.20M | 27.98M | 7.00M | 7.26M | 6.87M | 6.95M | 3.49M |
EBITDA | -133.69M | 129.33M | 300.87M | 79.83M | 113.44M | 91.63M | 51.08M | 20.23M |
EBITDA Ratio | -52.61% | 26.22% | 49.15% | 36.83% | 45.15% | 43.41% | 36.21% | 23.72% |
Operating Income | -115.18M | 98.11M | 268.28M | 75.10M | 105.24M | 84.80M | 44.46M | 16.48M |
Operating Income Ratio | -45.33% | 14.28% | 44.90% | 29.06% | 44.00% | 41.38% | 32.24% | 18.93% |
Total Other Income/Expenses | -7.75M | -3.22M | -237.55K | -1.16M | 28.04M | -120.38K | -343.78K | 10.53M |
Income Before Tax | -122.93M | 94.89M | 268.04M | 73.94M | 106.04M | 84.68M | 44.11M | 27.01M |
Income Before Tax Ratio | -48.38% | 13.81% | 44.86% | 28.61% | 44.33% | 41.32% | 31.99% | 31.03% |
Income Tax Expense | 7.19M | 12.22M | 31.57M | 8.49M | 13.75M | 10.77M | 4.85M | 3.59M |
Net Income | -184.91M | 82.97M | 236.51M | 65.45M | 92.31M | 73.94M | 39.29M | 23.44M |
Net Income Ratio | -72.77% | 12.08% | 39.58% | 25.32% | 38.59% | 36.08% | 28.50% | 26.93% |
EPS | -0.46 | 0.21 | 0.59 | 0.16 | 0.23 | 0.75 | 0.54 | 2.34 |
EPS Diluted | -0.46 | 0.21 | 0.59 | 0.16 | 0.23 | 0.75 | 0.54 | 2.34 |
Weighted Avg Shares Out | 401.97M | 400.86M | 400.86M | 400.86M | 400.86M | 98.58M | 72.76M | 10.02M |
Weighted Avg Shares Out (Dil) | 401.97M | 400.86M | 400.86M | 400.86M | 400.86M | 98.58M | 72.76M | 10.02M |
Source: https://incomestatements.info
Category: Stock Reports